Medicare Program; Meeting of the Medicare Evidence Development & Coverage Advisory Committee-(MedCAC), 34469-34470 [E7-12046]
Download as PDF
Federal Register / Vol. 72, No. 120 / Friday, June 22, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
Medicare Program; Meeting of the
Medicare Evidence Development &
Coverage Advisory Committee—
(MedCAC)
September 12, 2007.
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: This notice announces a
public meeting of the Medicare
Evidence Development and Coverage
Advisory Committee (MedCAC)
(Committee). Among other things, the
Committee provides advice and
recommendations about whether
scientific evidence is adequate to
determine whether certain medical
items and services are reasonable and
necessary under the Medicare statute.
This meeting will consider the evidence
on the diagnostic criteria for obstructive
sleep apnea (OSA) in Medicare
beneficiaries who may be candidates for
continuous positive airway pressure
(CPAP) therapy and alternatives to
facility-based polysomnography (PSG)
in the diagnosis of OSA, including
home sleep testing devices and clinical
diagnosis without the use of sleep
testing.
This meeting is given under the
Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)).
DATES: The public meeting will be held
on Wednesday, September 12, 2007
from 7:30 a.m. until 4:30 p.m., daylight
savings time (d.s.t).
Deadline for Presentations and
Comments: Send written comments and
presentations to the address specified in
the ADDRESSES section by 5 p.m., d.s.t.
on August 13, 2007. Please note that the
presentation you submit will be final, as
no further changes to the presentation
will be accepted after submission.
Deadline for Meeting Registration: For
security reasons, individuals wishing to
attend this meeting must register by 5
p.m., d.s.t. on September 5, 2007.
Deadline for Submitting Request for
Special Accommodations: Persons
attending the meeting who are hearing
or visually impaired, or have a
condition that requires special
assistance or accommodations, are
asked to notify the Executive Secretary
as specified in the FOR FURTHER
INFORMATION CONTACT section of this
notice.
ADDRESSES: Meeting Location: The
meeting will be held in the main
VerDate Aug<31>2005
16:51 Jun 21, 2007
Jkt 211001
auditorium of the Centers for Medicare
& Medicaid Services, 7500 Security
Boulevard, Baltimore, MD 21244.
Registration: Register by contacting
Maria Ellis 410–786–0309;
Maria.Ellis@cms.hhs.gov; Centers for
Medicare & Medicaid Services, OCSQCoverage and Analysis Group, C1–09–
06, 7500 Security Boulevard, Baltimore,
MD 21244.
Presentation and Comment
Submission: Submit presentation and
comments to Michelle Atkinson,
Centers for Medicare & Medicaid
Services, OCSQ-Coverage and Analysis
Group, C1–09–06, 7500 Security
Boulevard, Baltimore, MD 21244.
Web site: You may access up-to-date
information on this meeting at https://
www.cms.hhs.gov/FACA/
02_MCAC.asp#TopOfPage.
Submission of Presentations and
Comments: Interested persons may
present data, information, or views
orally or in writing on issues pending
before the Committee. Please submit
written comments and presentations to
the Executive Secretary at the address
specified in the ADDRESSES section of
this notice.
FOR FURTHER INFORMATION CONTACT:
Michelle Atkinson, Executive Secretary
for MedCAC, (410–786–2881;
Michelle.Atkinson@cms.hhs.gov).
SUPPLEMENTARY INFORMATION:
I. Meeting Topic
On December 14, 1998, we published
a notice in the Federal Register (63 FR
68780) to describe the Medicare
Coverage Advisory Committee (MCAC),
which provides advice and
recommendations to CMS about clinical
issues. The MCAC was subsequently
rechartered as the Medicare Evidence
Development and Coverage Advisory
Committee (MedCAC).
This notice announces the September
12, 2007 public meeting of the
Committee.
This meeting will inform CMS in its
reconsideration of the Medicare
National Coverage Determination (NCD)
on continuous positive airway pressure
(CPAP) therapy for OSA. We received a
complete formal written request from
the American Academy of
Otolaryngology-Head and Neck Surgery
to modify the NCD to include the use of
portable multichannel home sleep
testing devices as an alternative to
facility-based polysomnography (PSG)
in the evaluation of OSA. In addition,
we received an incomplete request from
a Medicare beneficiary, numerous
informal requests from stakeholders,
and interest from Medicare contractors
concerning the criteria for determining
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
34469
the apnea-hypopnea index (AHI) in
sleep testing. We are also aware of
recently published research suggesting a
benefit for the use of CPAP without
prior sleep testing in selected
populations (trial of CPAP).
During this meeting, the Committee
will consider evidence and hear
presentations and public comments on
the use of home sleep testing devices or
clinical diagnosis as an alternative to
facility-based PSG in the diagnosis or
both of obstructive sleep apnea (OSA);
the criteria for determining the AHI; the
use of clinical signs, symptoms or
patient questionnaire results to establish
a diagnosis of OSA; and the
generalizability of the evidence to the
Medicare beneficiary population.
Background information about this
topic, including panel materials, is
available on the Internet at https://
www.cms.hhs.gov/coverage/.
II. Meeting Procedures
This meeting is open to the public.
The Committee will hear oral
presentations from the public for
approximately 45 minutes. The
Committee may limit the number and
duration of oral presentations to the
time available. If you wish to make
formal presentations, you must notify
the Executive Secretary as specified in
FOR FURTHER INFORMATION CONTACT
section of the notice and submit the
following to the address specified in the
ADDRESSES section of this notice by the
date specified in the DATES section of
this notice: (1) A brief statement of the
general nature of the evidence or
arguments you wish to present; (2) the
names and addresses of proposed
participants; and (3) a written copy of
your presentation. Your presentation
should consider the questions we have
posed to the Committee and focus on
the issues specific to the topic. The
questions will be available on the
following Web site: https://
www.cms.hhs.gov/FACA/
02_MCAC.asp#TopOfPage. We require
that you declare at the meeting whether
you have any financial involvement
with manufacturers of any items or
services being discussed (or with their
competitors).
After the public and CMS
presentations, the Committee will
deliberate openly on the topic.
Interested persons may observe the
deliberations, but the Committee will
not hear further comments during this
time except at the request of the
chairperson. The Committee will also
allow a 15 minute unscheduled open
public session for any attendee to
address issues specific to the topic. At
the conclusion of the day, the members
E:\FR\FM\22JNN1.SGM
22JNN1
34470
Federal Register / Vol. 72, No. 120 / Friday, June 22, 2007 / Notices
will vote and the Committee will make
its recommendation.
III. Registration Instructions
The Coverage and Analysis Group is
coordinating meeting registration. While
there is no registration fee, individuals
must register to attend. Register by
contacting Maria Ellis at the address
specified in the ADDRESSES section of
this notice. Please provide your name,
address, organization, telephone and fax
numbers, and e-mail address.
You will receive a registration
confirmation with instructions for your
arrival at the CMS complex. You will be
notified if the seating capacity has been
reached.
This meeting is located on Federal
property; therefore, for security reasons,
any individuals wishing to attend this
meeting must register by 5 p.m. d.s.t. on
September 5, 2007.
IV. Security, Building, and Parking
Guidelines
This meeting will be held in a Federal
government building; therefore, Federal
security measures are applicable. In
planning your arrival time, we
recommend allowing additional time to
clear security.
In order to gain access to the building
and grounds, individuals must present
photographic identification to the
Federal Protective Service or Guard
Service personnel before being allowed
entrance.
Security measures also include
inspection of vehicles, inside and out, at
the entrance to the grounds. In addition,
all individuals entering the building
must pass through a metal detector. All
items brought to CMS, whether personal
or for the purpose of demonstration or
to support a demonstration, are subject
to inspection. We cannot assume
responsibility for coordinating the
receipt, transfer, transport, storage, setup, safety, or timely arrival of any
personal belongings or items used for
demonstration or to support a
demonstration.
Parking permits and instructions will
be issued upon arrival.
Note: Individuals who are not registered in
advance will not be permitted to enter the
building and will be unable to attend the
meeting. The public may not enter the
building earlier than 30 to 45 minutes prior
to the convening of the meeting.
All visitors must be escorted in areas
other than the lower and first floor
levels in the Central Building.
Authority: 5 U.S.C. App. 2, section 10(a).
(Catalog of Federal Domestic Assistance
Program No. 93.774, Medicare—
Supplementary Medical Insurance Program)
Dated: June 11, 2007.
Barry M. Straube,
Chief Medical Officer and Director, Office
of Clinical Standards and Quality, Centers
for Medicare & Medicaid Services.
[FR Doc. E7–12046 Filed 6–21–07; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2000D–0084]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Guidance for
Industry on Special Protocol
Assessment
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Fax written comments on the
collection of information by July 23,
2007.
DATES:
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974. All comments should be
identified with the OMB control number
0910–0470. Also include the FDA
docket number found in brackets in the
heading of this document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Elizabeth Berbakos, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857,301–827–
1482.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Guidance for Industry on Special
Protocol Assessment (OMB Control
Number 0910–0470)—Extension
In the Federal Registerof July 31,
2006 (71 FR 43199), FDA published a
60-day notice requesting public
comment on the information collection
provisions. No comments were received.
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
No. of
Respondents
Notification for Carcinogenicity Protocols
Annual Frequency per
Response
Total Annual
Responses
Hours per
Response
21
2.19
46
8
368
151
Requests for Special Protocol
Assessment
2.48
374
15
5,610
Total
rwilkins on PROD1PC63 with NOTICES
1There
Total Hours
5,978
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Aug<31>2005
16:51 Jun 21, 2007
Jkt 211001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
E:\FR\FM\22JNN1.SGM
22JNN1
Agencies
[Federal Register Volume 72, Number 120 (Friday, June 22, 2007)]
[Notices]
[Pages 34469-34470]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12046]
[[Page 34469]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
Medicare Program; Meeting of the Medicare Evidence Development &
Coverage Advisory Committee--(MedCAC)
September 12, 2007.
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces a public meeting of the Medicare
Evidence Development and Coverage Advisory Committee (MedCAC)
(Committee). Among other things, the Committee provides advice and
recommendations about whether scientific evidence is adequate to
determine whether certain medical items and services are reasonable and
necessary under the Medicare statute. This meeting will consider the
evidence on the diagnostic criteria for obstructive sleep apnea (OSA)
in Medicare beneficiaries who may be candidates for continuous positive
airway pressure (CPAP) therapy and alternatives to facility-based
polysomnography (PSG) in the diagnosis of OSA, including home sleep
testing devices and clinical diagnosis without the use of sleep
testing.
This meeting is given under the Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)).
DATES: The public meeting will be held on Wednesday, September 12, 2007
from 7:30 a.m. until 4:30 p.m., daylight savings time (d.s.t).
Deadline for Presentations and Comments: Send written comments and
presentations to the address specified in the ADDRESSES section by 5
p.m., d.s.t. on August 13, 2007. Please note that the presentation you
submit will be final, as no further changes to the presentation will be
accepted after submission.
Deadline for Meeting Registration: For security reasons,
individuals wishing to attend this meeting must register by 5 p.m.,
d.s.t. on September 5, 2007.
Deadline for Submitting Request for Special Accommodations: Persons
attending the meeting who are hearing or visually impaired, or have a
condition that requires special assistance or accommodations, are asked
to notify the Executive Secretary as specified in the FOR FURTHER
INFORMATION CONTACT section of this notice.
ADDRESSES: Meeting Location: The meeting will be held in the main
auditorium of the Centers for Medicare & Medicaid Services, 7500
Security Boulevard, Baltimore, MD 21244.
Registration: Register by contacting Maria Ellis 410-786-0309;
Maria.Ellis@cms.hhs.gov; Centers for Medicare & Medicaid Services,
OCSQ-Coverage and Analysis Group, C1-09-06, 7500 Security Boulevard,
Baltimore, MD 21244.
Presentation and Comment Submission: Submit presentation and
comments to Michelle Atkinson, Centers for Medicare & Medicaid
Services, OCSQ-Coverage and Analysis Group, C1-09-06, 7500 Security
Boulevard, Baltimore, MD 21244.
Web site: You may access up-to-date information on this meeting at
https://www.cms.hhs.gov/FACA/02_MCAC.asp#TopOfPage.
Submission of Presentations and Comments: Interested persons may
present data, information, or views orally or in writing on issues
pending before the Committee. Please submit written comments and
presentations to the Executive Secretary at the address specified in
the ADDRESSES section of this notice.
FOR FURTHER INFORMATION CONTACT: Michelle Atkinson, Executive Secretary
for MedCAC, (410-786-2881; Michelle.Atkinson@cms.hhs.gov).
SUPPLEMENTARY INFORMATION:
I. Meeting Topic
On December 14, 1998, we published a notice in the Federal Register
(63 FR 68780) to describe the Medicare Coverage Advisory Committee
(MCAC), which provides advice and recommendations to CMS about clinical
issues. The MCAC was subsequently rechartered as the Medicare Evidence
Development and Coverage Advisory Committee (MedCAC).
This notice announces the September 12, 2007 public meeting of the
Committee.
This meeting will inform CMS in its reconsideration of the Medicare
National Coverage Determination (NCD) on continuous positive airway
pressure (CPAP) therapy for OSA. We received a complete formal written
request from the American Academy of Otolaryngology-Head and Neck
Surgery to modify the NCD to include the use of portable multichannel
home sleep testing devices as an alternative to facility-based
polysomnography (PSG) in the evaluation of OSA. In addition, we
received an incomplete request from a Medicare beneficiary, numerous
informal requests from stakeholders, and interest from Medicare
contractors concerning the criteria for determining the apnea-hypopnea
index (AHI) in sleep testing. We are also aware of recently published
research suggesting a benefit for the use of CPAP without prior sleep
testing in selected populations (trial of CPAP).
During this meeting, the Committee will consider evidence and hear
presentations and public comments on the use of home sleep testing
devices or clinical diagnosis as an alternative to facility-based PSG
in the diagnosis or both of obstructive sleep apnea (OSA); the criteria
for determining the AHI; the use of clinical signs, symptoms or patient
questionnaire results to establish a diagnosis of OSA; and the
generalizability of the evidence to the Medicare beneficiary
population.
Background information about this topic, including panel materials,
is available on the Internet at https://www.cms.hhs.gov/coverage/.
II. Meeting Procedures
This meeting is open to the public. The Committee will hear oral
presentations from the public for approximately 45 minutes. The
Committee may limit the number and duration of oral presentations to
the time available. If you wish to make formal presentations, you must
notify the Executive Secretary as specified in FOR FURTHER INFORMATION
CONTACT section of the notice and submit the following to the address
specified in the ADDRESSES section of this notice by the date specified
in the DATES section of this notice: (1) A brief statement of the
general nature of the evidence or arguments you wish to present; (2)
the names and addresses of proposed participants; and (3) a written
copy of your presentation. Your presentation should consider the
questions we have posed to the Committee and focus on the issues
specific to the topic. The questions will be available on the following
Web site: https://www.cms.hhs.gov/FACA/02_MCAC.asp#TopOfPage. We
require that you declare at the meeting whether you have any financial
involvement with manufacturers of any items or services being discussed
(or with their competitors).
After the public and CMS presentations, the Committee will
deliberate openly on the topic. Interested persons may observe the
deliberations, but the Committee will not hear further comments during
this time except at the request of the chairperson. The Committee will
also allow a 15 minute unscheduled open public session for any attendee
to address issues specific to the topic. At the conclusion of the day,
the members
[[Page 34470]]
will vote and the Committee will make its recommendation.
III. Registration Instructions
The Coverage and Analysis Group is coordinating meeting
registration. While there is no registration fee, individuals must
register to attend. Register by contacting Maria Ellis at the address
specified in the ADDRESSES section of this notice. Please provide your
name, address, organization, telephone and fax numbers, and e-mail
address.
You will receive a registration confirmation with instructions for
your arrival at the CMS complex. You will be notified if the seating
capacity has been reached.
This meeting is located on Federal property; therefore, for
security reasons, any individuals wishing to attend this meeting must
register by 5 p.m. d.s.t. on September 5, 2007.
IV. Security, Building, and Parking Guidelines
This meeting will be held in a Federal government building;
therefore, Federal security measures are applicable. In planning your
arrival time, we recommend allowing additional time to clear security.
In order to gain access to the building and grounds, individuals
must present photographic identification to the Federal Protective
Service or Guard Service personnel before being allowed entrance.
Security measures also include inspection of vehicles, inside and
out, at the entrance to the grounds. In addition, all individuals
entering the building must pass through a metal detector. All items
brought to CMS, whether personal or for the purpose of demonstration or
to support a demonstration, are subject to inspection. We cannot assume
responsibility for coordinating the receipt, transfer, transport,
storage, set-up, safety, or timely arrival of any personal belongings
or items used for demonstration or to support a demonstration.
Parking permits and instructions will be issued upon arrival.
Note: Individuals who are not registered in advance will not be
permitted to enter the building and will be unable to attend the
meeting. The public may not enter the building earlier than 30 to 45
minutes prior to the convening of the meeting.
All visitors must be escorted in areas other than the lower and
first floor levels in the Central Building.
Authority: 5 U.S.C. App. 2, section 10(a).
(Catalog of Federal Domestic Assistance Program No. 93.774,
Medicare--Supplementary Medical Insurance Program)
Dated: June 11, 2007.
Barry M. Straube,
Chief Medical Officer and Director, Office of Clinical Standards and
Quality, Centers for Medicare & Medicaid Services.
[FR Doc. E7-12046 Filed 6-21-07; 8:45 am]
BILLING CODE 4120-01-P